Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.

2.

Stabilization of short collagen-like triple helices by protein engineering.

Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, Bann J, Guo Y, Lustig A, Bächinger HP, Engel J.

J Mol Biol. 2001 May 18;308(5):1081-9.

PMID:
11352592
3.

Protein design of an HIV-1 entry inhibitor.

Root MJ, Kay MS, Kim PS.

Science. 2001 Feb 2;291(5505):884-8.

5.

HIV-1 membrane fusion: targets of opportunity.

Doms RW, Moore JP.

J Cell Biol. 2000 Oct 16;151(2):F9-14. No abstract available.

7.

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.

Yang X, Florin L, Farzan M, Kolchinsky P, Kwong PD, Sodroski J, Wyatt R.

J Virol. 2000 May;74(10):4746-54.

8.

Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor.

Mirzabekov T, Bannert N, Farzan M, Hofmann W, Kolchinsky P, Wu L, Wyatt R, Sodroski J.

J Biol Chem. 1999 Oct 1;274(40):28745-50.

9.

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

VanCott TC, Mascola JR, Loomis-Price LD, Sinangil F, Zitomersky N, McNeil J, Robb ML, Birx DL, Barnett S.

J Virol. 1999 Jun;73(6):4640-50.

10.

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ.

AIDS. 1998 Dec 24;12(18):2407-15.

PMID:
9875578
11.

Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.

Schønning K, Bolmstedt A, Novotny J, Lund OS, Olofsson S, Hansen JE.

AIDS Res Hum Retroviruses. 1998 Nov 1;14(16):1451-6.

PMID:
9824323
12.

Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.

Farzan M, Choe H, Desjardins E, Sun Y, Kuhn J, Cao J, Archambault D, Kolchinsky P, Koch M, Wyatt R, Sodroski J.

J Virol. 1998 Sep;72(9):7620-5.

13.

Why do we not have an HIV vaccine and how can we make one? .

Burton DR, Moore JP.

Nat Med. 1998 May;4(5 Suppl):495-8. No abstract available.

PMID:
9585194
14.

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, Sodroski J.

J Virol. 1998 Jun;72(6):4694-703.

15.

Capture of an early fusion-active conformation of HIV-1 gp41.

Furuta RA, Wild CT, Weng Y, Weiss CD.

Nat Struct Biol. 1998 Apr;5(4):276-9. Erratum in: Nat Struct Biol 1998 Jul;5(7):612.

PMID:
9546217
16.

Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.

Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM.

J Virol. 1998 Feb;72(2):1552-76.

17.

Atomic structure of a thermostable subdomain of HIV-1 gp41.

Tan K, Liu J, Wang J, Shen S, Lu M.

Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12303-8.

18.

Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain.

Tao Y, Strelkov SV, Mesyanzhinov VV, Rossmann MG.

Structure. 1997 Jun 15;5(6):789-98.

19.

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.

Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, Walker CM, Steimer KS.

Vaccine. 1997 Jun;15(8):869-73.

PMID:
9234536
20.

Atomic structure of the ectodomain from HIV-1 gp41.

Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC.

Nature. 1997 May 22;387(6631):426-30.

PMID:
9163431

Supplemental Content

Support Center